You can now read 10 articles each month for free on BostonGlobe.com.

The Boston Globe

Business

mass. movers

Alnylam reports early success with drug

RNA interference (RNAi) technology is used to turn off disease-causing genes.

Globe File photo/2013

RNA interference (RNAi) technology is used to turn off disease-causing genes.

Continue reading below

Alnylam Pharmaceuticals Inc. stock climbed after the Cambridge company reported positive early trial results for an experimental RNA interference drug, ALN-TTRsc. It’s designed to treat transthyretin familial amyloidosis, a rare genetic condition in which a starchy protein builds up in organs and tissues. ALN-TTRsc was evaluated for a form of the disease typically treated with a liver transplant. Alnylam will start a late-stage trial of the drug in 2014. It’s developing the drug in partnership with Genzyme.

You have reached the limit of 10 free articles a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than $1 a week